Watson P R, Brubaker L H, Yaghmai F
Cancer Treat Rep. 1985 Mar;69(3):313-4.
A patient with acute erythroleukemia secondary to polycythemia vera was treated iv with high-dose cytarabine at a dose of 3 g/m2 every 12 hours. After the fourth dose, he developed an expressive (Broca's type) aphasia and somnolence, which progressed until after the treatment was stopped at the seventh dose. The somnolence cleared partially during the next 2 weeks but recurred after cytarabine was restarted at a dose of 100 mg/m2 daily for 7 days. The patient died 5 days later of refractory extreme thrombocytopenia and bleeding. The normal spinal fluid obtained during life and the postmortem findings were consistent with previously reported findings with central nervous system toxicity from high-dose cytarabine. Three unusual aspects of this case are early onset of symptoms, expressive aphasia as the dominant manifestation, and exacerbation of symptoms with standard doses (100 mg/m2/day).
一名真性红细胞增多症继发急性红白血病的患者接受了静脉注射高剂量阿糖胞苷治疗,剂量为每12小时3 g/m²。在第四次给药后,他出现了表达性(布罗卡型)失语和嗜睡,症状持续进展,直至第七次给药后治疗停止。嗜睡在接下来的2周内部分缓解,但在阿糖胞苷以每日100 mg/m²的剂量重新开始使用7天后复发。患者在5天后死于难治性严重血小板减少症和出血。生前获得的正常脑脊液及尸检结果与先前报道的高剂量阿糖胞苷所致中枢神经系统毒性的结果一致。该病例的三个不寻常之处在于症状的早期出现、以表达性失语为主要表现以及标准剂量(100 mg/m²/天)时症状加重。